GlobeNewswire: Cellular Biomedicine Group Inc. Contains the last 10 of 150 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:38:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/18/1668620/0/en/Cellular-Biomedicine-Group-Appoints-CAR-T-Pioneer-Dr-Stephan-A-Grupp-as-Member-of-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp as Member of Scientific Advisory Board2018-12-18T12:30:00Z<![CDATA[SHANGHAI, China and NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the appointment of Dr. Stephan A. Grupp, a CAR-T pioneer and pediatric oncologist, to CBMG’s Scientific Advisory Board to impart scientific vigor and clinical guidance in the Company’s immuno-oncology pipeline.]]>https://www.globenewswire.com/news-release/2018/11/06/1645837/0/en/Cellular-Biomedicine-Group-Reports-Third-Quarter-Financial-Results-and-Recent-Business-Highlights.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlights2018-11-06T11:56:34Z<![CDATA[SHANGHAI, China and NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the third quarter ended September 30, 2018.]]>Immuno-Oncology Pipeline UpdateCellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlightshttps://www.globenewswire.com/news-release/2018/10/25/1627179/0/en/Cellular-Biomedicine-Group-to-Provide-Company-Cancer-Immunotherapy-Pipeline-Update-and-Facility-Tour-for-Attendees-of-the-Advanced-Cell-Therapy-Summit-in-Shanghai.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai2018-10-25T12:56:42Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, will provide a Company cancer immunotherapy pipeline update and host a tour of its GMP facility for attendees of the Advanced Cell Therapy Summit 2018 in Shanghai on Monday, October 29, 2018. CBMG will host international attendees of the Summit comprised of key opinion leaders, investment and industry executives to tour its flagship GMP facility in Shanghai, and the Company’s Chief Executive Officer and Chief Scientific Officer will present an update on its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors, including:]]>https://www.globenewswire.com/news-release/2018/10/03/1600644/0/en/Cellular-Biomedicine-Group-Obtained-NCI-Patent-License-for-Next-Generation-Neoantigen-Reactive-Tumor-Infiltrating-Lymphocyte-TIL-Technology-to-Treat-Solid-Tumors.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat Solid Tumors2018-10-03T11:30:00Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement (the “License Agreement”) with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services. Pursuant to the License Agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancers.]]>https://www.globenewswire.com/news-release/2018/09/27/1577096/0/zh-hans/CBMG-%E8%A5%BF%E6%AF%94%E6%9B%BC%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80%E9%9B%86%E5%9B%A2-%E9%92%88%E5%AF%B9%E4%B8%AD%E5%9B%BD%E6%82%A3%E8%80%85%E4%B8%8E-CAR-T-%E7%BB%86%E8%83%9E%E6%B2%BB%E7%96%97%E9%A2%86%E5%9F%9F%E7%9A%84%E5%85%A8%E7%90%83%E9%A2%86%E5%AF%BC%E8%80%85%E8%BE%BE%E6%88%90%E6%88%98%E7%95%A5%E8%AE%B8%E5%8F%AF%E5%92%8C%E5%90%88%E4%BD%9C%E5%8D%8F%E8%AE%AE.html?f=22&fvtc=4&fvtv=20726CBMG(西比曼生物科技集团)针对中国患者与 CAR-T 细胞治疗领域的全球领导者达成战略许可和合作协议2018-09-27T11:42:47Z<![CDATA[与诺华公司的合作内容包括以 4,000 万美元收购 CBMG 的1,458,257 股股票,对其开展股权投资,股票价格为每股 27.43 美元CBMG 将授权诺华公司在全球范围内使用其特定专有技术CBMG 将在中国生产和供应 Kymriah® (tisagenlecleucel)]]>https://www.globenewswire.com/news-release/2018/09/24/1574940/0/en/Cellular-Biomedicine-Group-to-Present-at-the-Cantor-Fitzgerald-2018-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference2018-09-24T12:15:29Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that management will present a Company update and host investor meetings at the Cantor Fitzgerald 2018 Global Healthcare Conference.]]>https://www.globenewswire.com/news-release/2018/08/28/1557679/0/en/Cellular-Biomedicine-Group-to-Present-on-Three-Panels-at-B-Riley-FBR-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group to Present on Three Panels at B. Riley FBR Annual Healthcare Conference2018-08-28T13:16:20Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company will present on three panels at the B. Riley FBR Annual Healthcare Conference to be held on September 4, 2018 in New York City, as well as meeting with investors.]]>https://www.globenewswire.com/news-release/2018/08/08/1548821/0/en/Cellular-Biomedicine-Group-Reports-Second-Quarter-and-First-Half-2018-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights2018-08-08T11:31:01Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the second quarter and six months ended June 30, 2018.]]>Current Immuno-Oncology PipelineCurrent Immuno-Oncology Pipeline of Targeted Indications and Potential Therapieshttps://www.globenewswire.com/news-release/2018/06/22/1528374/0/en/Cellular-Biomedicine-Group-Announces-Grand-Opening-of-Global-Research-and-Development-Center-in-Gaithersburg-Maryland.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland2018-06-22T13:00:00Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the grand opening of a new research and development center in Gaithersburg, Maryland.]]>https://www.globenewswire.com/news-release/2018/06/21/1527743/0/en/Cellular-Biomedicine-Group-to-Present-a-Keynote-Address-at-CAR-TCR-Summit-Asia.html?f=22&fvtc=4&fvtv=20726Cellular Biomedicine Group to Present a Keynote Address at CAR-TCR Summit Asia2018-06-21T11:30:00Z<![CDATA[SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, will participate in the upcoming CAR-TCR Summit Asia to be held in Singapore, June 27-28, 2018. The Company’s CEO, Tony (Bizuo) Liu, will present a keynote address entitled “Digital Decades Ahead For Biotech” as part of the “Manufacturing Scale Up & Automation” portion of the Summit. The Summit hosts key opinion leaders in CAR-TCR development as they build their development strategy to bring safe and effective CAR-T and TCR therapies to patients globally.]]>